Stock Track | CStone Pharma Soars 5.51% Intraday on Strong 2025 Results and Promising Pipeline Progress

Stock Track09:39

CStone Pharmaceuticals' stock surged 5.51% during intraday trading on Friday, following the release of its 2025 annual results which highlighted significant strategic and clinical advancements.

The company's detailed earnings report pointed to a pivotal strategic inflection point, with rapid progress across its core R&D pipeline. Key asset CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, showed compelling efficacy data, including a 90% objective response rate in first-line NSCLC patients with high PD-L1 expression. Furthermore, the company successfully expanded the global commercialization footprint of its anti-PD-L1 antibody sugemalimab to over 60 countries and secured important National Reimbursement Drug List (NRDL) inclusions and renewals for its commercial products in China, setting the stage for future revenue growth.

Despite reporting an annual loss, which the company attributed primarily to one-time costs related to preparing pralsetinib for NRDL negotiation, CStone emphasized its solid financial position with cash reserves of RMB918.7 million. Management expressed confidence in the anticipated revenue ramp-up from 2026 onwards and outlined plans to initiate global Phase III trials for CS2009 by the end of the year, reinforcing investor optimism about the company's long-term prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1134940401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134940401","market":"us","top_or_hot":-1,"title":"Stock Track | CStone Pharma Soars 5.51% Intraday on Strong 2025 Results and Promising Pipeline Progress","media":"Stock Track","content":"<p>CStone Pharmaceuticals' stock surged 5.51% during intraday trading on Friday, following the release of its 2025 annual results which highlighted significant strategic and clinical advancements.</p><p>The company's detailed earnings report pointed to a pivotal strategic inflection point, with rapid progress across its core R&D pipeline. Key asset CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, showed compelling efficacy data, including a 90% objective response rate in first-line NSCLC patients with high PD-L1 expression. Furthermore, the company successfully expanded the global commercialization footprint of its anti-PD-L1 antibody sugemalimab to over 60 countries and secured important National Reimbursement Drug List (NRDL) inclusions and renewals for its commercial products in China, setting the stage for future revenue growth.</p><p>Despite reporting an annual loss, which the company attributed primarily to one-time costs related to preparing pralsetinib for NRDL negotiation, CStone emphasized its solid financial position with cash reserves of RMB918.7 million. Management expressed confidence in the anticipated revenue ramp-up from 2026 onwards and outlined plans to initiate global Phase III trials for CS2009 by the end of the year, reinforcing investor optimism about the company's long-term prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CStone Pharma Soars 5.51% Intraday on Strong 2025 Results and Promising Pipeline Progress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CStone Pharma Soars 5.51% Intraday on Strong 2025 Results and Promising Pipeline Progress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-27 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CStone Pharmaceuticals' stock surged 5.51% during intraday trading on Friday, following the release of its 2025 annual results which highlighted significant strategic and clinical advancements.</p><p>The company's detailed earnings report pointed to a pivotal strategic inflection point, with rapid progress across its core R&D pipeline. Key asset CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, showed compelling efficacy data, including a 90% objective response rate in first-line NSCLC patients with high PD-L1 expression. Furthermore, the company successfully expanded the global commercialization footprint of its anti-PD-L1 antibody sugemalimab to over 60 countries and secured important National Reimbursement Drug List (NRDL) inclusions and renewals for its commercial products in China, setting the stage for future revenue growth.</p><p>Despite reporting an annual loss, which the company attributed primarily to one-time costs related to preparing pralsetinib for NRDL negotiation, CStone emphasized its solid financial position with cash reserves of RMB918.7 million. Management expressed confidence in the anticipated revenue ramp-up from 2026 onwards and outlined plans to initiate global Phase III trials for CS2009 by the end of the year, reinforcing investor optimism about the company's long-term prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"","article_id":"1134940401","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134940401","pubTimestamp":1774575550,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CStone Pharmaceuticals' stock surged 5.51% during intraday trading on Friday, following the release of its 2025 annual results which highlighted significant strategic and clinical advancements.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B"},"translate_title":"个股赛道|基石药业盘中大涨5.51%2025业绩强劲管线进展喜人","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1},"content_text":"CStone Pharmaceuticals' stock surged 5.51% during intraday trading on Friday, following the release of its 2025 annual results which highlighted significant strategic and clinical advancements.The company's detailed earnings report pointed to a pivotal strategic inflection point, with rapid progress across its core R&D pipeline. Key asset CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, showed compelling efficacy data, including a 90% objective response rate in first-line NSCLC patients with high PD-L1 expression. Furthermore, the company successfully expanded the global commercialization footprint of its anti-PD-L1 antibody sugemalimab to over 60 countries and secured important National Reimbursement Drug List (NRDL) inclusions and renewals for its commercial products in China, setting the stage for future revenue growth.Despite reporting an annual loss, which the company attributed primarily to one-time costs related to preparing pralsetinib for NRDL negotiation, CStone emphasized its solid financial position with cash reserves of RMB918.7 million. Management expressed confidence in the anticipated revenue ramp-up from 2026 onwards and outlined plans to initiate global Phase III trials for CS2009 by the end of the year, reinforcing investor optimism about the company's long-term prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1134940401","isCrawlerRequest":true}